Icahn Institute for Data Science and Genomic Technology

Icahn Institute for Data Science and Genomic Technology
Name	Icahn Institute for Data Science and Genomic Technology
Established	2013
Parent	Icahn School of Medicine at Mount Sinai
Director	Eric E. Schadt
City	New York City
State	New York
Country	United States

Icahn Institute for Data Science and Genomic Technology. It is a premier interdisciplinary research center dedicated to advancing precision medicine through the integration of genomics, data science, and systems biology. Established within the Icahn School of Medicine at Mount Sinai, the institute leverages large-scale biological data to transform the understanding and treatment of complex diseases. Its work is central to the mission of the Mount Sinai Health System in pioneering next-generation healthcare.

History and establishment

The institute was founded in 2013 through a transformative gift from financier and philanthropist Carl Icahn. Its creation was a strategic initiative by the leadership of the Icahn School of Medicine at Mount Sinai, including then-Dean Dennis S. Charney, to position the institution at the forefront of the biomedical research revolution. The establishment coincided with the national Big Data to Knowledge (BD2K) initiative and the growing emphasis on precision medicine by the National Institutes of Health. Under the founding leadership of computational biologist Eric E. Schadt, the institute was designed to break down traditional silos between bioinformatics, clinical research, and basic science.

Research focus and scientific programs

Core research integrates multi-omics data—including genomics, transcriptomics, proteomics, and metabolomics—with clinical electronic health records from the Mount Sinai Health System. A major focus is constructing predictive network models of disease to identify novel therapeutic targets and biomarkers for conditions like Alzheimer's disease, autism spectrum disorder, cardiovascular disease, and cancer. The institute develops advanced computational methods in machine learning and artificial intelligence for analyzing large-scale biobank data, such as that from the UK Biobank and the All of Us Research Program. Its scientists also engage in foundational research in population genetics and the microbiome.

Organizational structure and leadership

The institute operates as an integral component of the Icahn School of Medicine at Mount Sinai and is closely aligned with the Department of Genetics and Genomic Sciences. Eric E. Schadt serves as the founding director and the Jean C. and James W. Crystal Professor of Genomics. Research is conducted by a multidisciplinary faculty spanning the fields of computational biology, statistical genetics, and biomedical engineering. The leadership structure fosters collaboration with clinical departments across the Mount Sinai Health System, including the Tisch Cancer Institute and the Friedman Brain Institute. Governance and strategic direction are informed by an advisory board comprising leaders in academia and industry.

Key facilities and resources

Researchers have access to state-of-the-art core facilities within the Icahn School of Medicine at Mount Sinai, including high-throughput DNA sequencing laboratories and the Minerva Supercomputer, a dedicated high-performance computing cluster. The institute leverages the extensive clinical data infrastructure of the Mount Sinai Health System, one of the largest academic medical center networks in the New York metropolitan area. It also utilizes the BioMe Biobank, a rich repository of genetic and phenotypic data from over 50,000 Mount Sinai patients. These resources are housed within the Leon and Norma Hess Center for Science and Medicine.

Notable achievements and impact

The institute has produced seminal work in mapping disease networks, contributing significantly to the International Common Disease Alliance and the Psychiatric Genomics Consortium. Its researchers have identified genetic risk factors for severe outcomes in COVID-19 through studies like the COVID-19 Host Genetics Initiative. Work led by scientists such as Joseph D. Buxbaum has advanced the understanding of the genetic architecture of autism spectrum disorder. The institute's data-driven approaches have directly influenced clinical trial design at the Tisch Cancer Institute and spurred the creation of several biotechnology startups focused on drug discovery.

Collaborations and partnerships

The institute maintains extensive collaborations with leading research organizations worldwide, including the Broad Institute, the Wellcome Sanger Institute, and Stanford University. It is a key participant in major consortia like the Accelerating Medicines Partnership and the All of Us Research Program led by the National Institutes of Health. Industrial partnerships with companies such as Regeneron Pharmaceuticals, Pfizer, and Google accelerate the translation of computational findings into clinical applications. These collaborations are further strengthened through shared initiatives with other New York-based institutions like the New York Genome Center and Rockefeller University.

Category:Research institutes in New York City Category:Genomics organizations Category:Icahn School of Medicine at Mount Sinai Category:Medical and health organizations based in New York City